GALT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GALT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Galectin Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.04 Mil.
Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Galectin Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $93.42 Mil.
The historical data trend for Galectin Therapeutics's Short-Term Debt & Capital Lease Obligation can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galectin Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Short-Term Debt & Capital Lease Obligation | Get a 7-Day Free Trial | 0.04 | 0.04 | 0.01 | 0.04 | 0.05 |
Galectin Therapeutics Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Short-Term Debt & Capital Lease Obligation | Get a 7-Day Free Trial | 0.04 | 0.05 | 0.05 | 0.05 | 0.04 |
This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.
In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.
Be Aware
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Thank you for viewing the detailed overview of Galectin Therapeutics's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.
Kary Eldred | director | 2121 RINGWOOD AVENUE, SAN JOSE CA 95131 |
Kevin D Freeman | director | 712 LAKEWAY DRIVE, KELLER TX 76248 |
Zordani Richard A. Jr. | director | 467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047 |
10x Fund, L.p. | 10 percent owner | 1099 FOREST LAKE TERRACE, NICEVILLE FL 32578 |
Elissa J. Schwartz | director | 235 SW CHURCH ST., PULLMAN WA 99163 |
Gilbert F Amelio | director | 5835 STRASBOURG COURT, ---, RENO NV 89511 |
Richard E Uihlein | director, 10 percent owner | 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158 |
Pol F Boudes | officer: Chief Medical Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Joel Lewis | director | 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158 |
Gilbert S Omenn | director | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Harold H. Shlevin | director, officer: Chief Executive Officer | C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071 |
Jack W Callicutt | officer: Chief Financial Officer | 75 FIFTH STREET NW STE. 313, ATLANTA GA 30308 |
Marc Rubin | director | C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080 |
James C Czirr | director | 4908 SOUTH ASHTON COURT, SPOKANE WA 99223 |
Peter G Traber | director, officer: President and CEO | 430 THAMER LANE, HOUSTON TX 77025 |
From GuruFocus
By GlobeNewswire • 09-13-2023
By Stock market mentor Stock market mentor • 01-24-2023
By Value_Insider Value_Insider • 11-29-2022
By Marketwired • 10-12-2023
By GuruFocus Research • 11-13-2023
By PurpleRose PurpleRose • 08-15-2022
By GuruFocusNews GuruFocusNews • 07-01-2022
By PurpleRose PurpleRose • 07-11-2022
By sperokesalga sperokesalga • 05-15-2023
By Marketwired • 11-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.